Evidence map›Paper›PMID 25565897›Full record

ReviewHIV/AIDS (Auckland, N.Z.)2015

Managing dyslipidemia in HIV/AIDS patients: challenges and solutions.

Nazik Elmalaika Os Husain, Mohamed H Ahmed

Open access · goldAbstract readReview
In one paragraph

Review in HIV/AIDS (Auckland, N.Z.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.Antimicrobial agents and chemotherapy · 2017
    Trial
  5. Metabolic and redox pathway dysregulation in HIV-associated coronary endothelial dysfunction.American journal of physiology. Heart and circulatory physiology · 2026
    Observational
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Novel Antiretroviral Structures from Marine Organisms.Molecules (Basel, Switzerland) · 2019
    Review
  19. Article
  20. Changes in Lipid Indices in HIV+ Cases on HAART.BioMed research international · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Nazik Elmalaika Os HusainDepartment of Pathology, Faculty of Medicine and Health Sciences, Omdurman Islamic University, Khartoum, Sudan.
Mohamed H AhmedDepartment of Medicine, Milton Keynes Hospital, NHS Foundation Trust, Milton Keynes, UK.
Milton Keynes Hospital NHS Foundation Trust · GBOmdurman Islamic University · SD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human immunodeficiency virus (HIV) is a chronic disease associated with dyslipidemia and insulin resistance. In addition, the administration of combination antiretroviral therapy is associated with an increase in the incidence of metabolic risk factors (insulin resistance, lipoatrophy, dyslipidemia, and abnormalities of fat distribution in HIV patients). HIV dyslipidemia is a common problem, and associated with an increase in incidence of cardiovascular disease. Further challenges in the management of HIV dyslipidemia are the presence of diabetes and metabolic syndrome, nonalcoholic fatty liver disease, hypothyroidism, chronic kidney disease, the risk of diabetes associated with statin administration, age and ethnicity, and early menopause in females. Dyslipidemia in patients with HIV is different from the normal population, due to the fact that HIV increases insulin resistance and HIV treatment not only may induce dyslipidemia but also may interact with lipid-lowering medication. The use of all statins (apart from simvastatin and lovastatin) is safe and effective in HIV dyslipidemia, and the addition of ezetimibe, fenofibrate, fish oil, and niacin can be used in statin-unresponsive HIV dyslipidemia. The management of dyslipidemia and cardiovascular disease risks associated with HIV is complex, and a certain number of patients may require management in specialist clinics run by specialist physicians in lipid disorders. Future research is needed to address best strategies in the management of hyperlipidemia with HIV infection.

Indexed as

cardiovascular diseasedylipidaemiafatty liverHIVinsulin resistancelipid lowering medication

Identifiers

PMID25565897
PMCPMC4274137
OpenAlexW1990308782

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.